Extracellular matrix modulation approaches
| Treatment | Impact on tumor | Impact on mAb tumor PK | mAb/tumor model | Source |
|---|---|---|---|---|
| Intratumoral collagenase | Collagen degradation | 80%–100% increase in diffusion 24 h after collagenase injection | Non-specific IgG (S1) HSTS-26T and U87 | 77 |
| Intravenous collagenase | Collagen degradation/decrease in tumor interstitial fluid pressure | 90%–140% increase in uptake at 24 h | TP-3 OHS | 79 |
| Relaxin infusion | Downregulation of tumor fibrosis/decrease collagen fiber length and signal | 80% increase in diffusion coefficient after a 12-day relaxin infusion | Non-specific IgG HSTS-26T | 78 |
| Intratumoral injection of bovine hyaluronidase | Hyaluronan degradation/decrease in interstitial fluid pressure | 70% increase in uptake 9 days after administration | TP-3 OHS | 80 |
| Pegylated human hyaluronidase (PEGPH20) | Tumor hyaluronan degradation | 100% increase in uptake 2 days after administration | Trastuzumab SKOV3-HAS2 | 82 |
| Pulsed ultrasound | Structural modification of extracellular matrix and widening of intercellular gaps | 36% Increase in tumor AUC (0–5 days) | MX-B3 A431 | 130 |